Method for providing natural therapeutic agents with high therapeutic index

• US 20040009161A1
• Filed: 12/10/2002
• Published: 01/15/2004
• Est. Priority Date: 11/07/2002
• Status: Abandoned Application

• Current Assignee: GenOdyssee S.A.
• Original Assignee: GenOdyssee S.A.
• Inventors: Escary, Jean-Louis
• Application Number:
  US10/315,493
• Publication Number:
  US 20040009161A1
• Time in Patent Office: Days
• US Class Current: 424/94.1
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/6866 Interferon

Abstract

Methods for identifying and providing new therapeutic agent(s) by selecting at least one polypeptide encoded by a natural allelic variant of one preselected gene having a therapeutic potential; determining the therapeutic index of the selected polypeptide(s) and retaining as therapeutic agent(s) those polypeptide(s) whose therapeutic index is higher than that of a reference agent.

Claims

1. A method for providing a therapeutic agent comprising the steps of:

a) providing a reference molecule having a therapeutic index;

b) selecting at least one polypeptide encoded by a natural allelic variant of one preselected gene or related gene or both and having therapeutic potential;

c) determining the therapeutic index of said at least one polypeptide selected in step b); and

d) retaining as a therapeutic agent, at least one polypeptide selected in step b) whose therapeutic index, as determined in step c), is higher than the therapeutic index of the reference molecule.

2. The method according to claim 1, wherein at least two polypeptides are selected in step b).

4. The method according to claim 1, wherein step c) comprises:

i) submitting the polypeptides selected in step b) to at least two activity tests;

ii) attributing a value to each polypeptide in direct relation with the results of said activity tests; and

iii) determining a therapeutic index for each polypeptide from the values attributed in step ii).

5. The method according to claim 1, wherein the polypeptides selected in step b) are selected from the group consisting of polypeptides encoded by natural allelic variants of one preselected gene with therapeutic potential and polypeptides encoded by natural allelic variants of at least one related gene.

6. The method according to claim 1, wherein said natural allelic variants originate from the human species.

7. The method according to claim 1, wherein the polypeptides selected in step b) are polypeptides encoded by natural allelic variants of a single gene that can be either the preselected gene with therapeutic potential or one related gene thereof.

8. The method according to claim 1, wherein said preselected gene with therapeutic potential is a gene encoding a cytokine.

9. A therapeutic agent comprising one or more compounds selected from the group consisting of a polypeptide selected according to claim 1, a polynucleotide encoding said polypeptide, a gene expression vector comprising said polynucleotide, and a host cell comprising said gene expression vector.

10. A therapeutic agent selected from the group consisting of a derivative of a polypeptide selected according to claim 1 wherein said derivative has been modified to increase the therapeutic index of said polypeptide, a derivative of a polynucleotide encoding a polypeptide selected according to claim 1, and combinations of the foregoing.

11. A therapeutic agent comprising a recombinant polypeptide whose amino acid sequence comprises more than one natural genetic variation characterizing the polypeptide selected according to claim 1.

12. A method for treating an individual in need thereof comprising administering to said individual a therapeutically effective amount of the therapeutic agent according to claim 9.

13. The method according to claim 1 wherein said therapeutic agent has a new pharmacological profile, a new therapeutic application, or both, with respect to a reference product.

14. The therapeutic agent of claim 10 wherein said modification to said derivative of a polypeptide is selected from the group consisting of PEGylation, glycosylation and succinylation.

15. The therapeutic agent of claim 10 wherein said derivative of a polynucleotide has been modified to increase the therapeutic index of the polypeptide encoded thereby pursuant to a method selected from site directed mutagenesis and directed evolution technologies.

3. A method for providing a therapeutic agent comprising the steps of:

a) selecting at least one polypeptide encoded by a natural allelic variant of a gene selected from the group consisting of one preselected gene with therapeutic potential, one related gene thereof and a combination thereof;

b) determining a therapeutic index for each polypeptide selected in step a);

c) identifying a polypeptide selected in step a) whose therapeutic index, as determined in step b), is higher than a therapeutic index of reference;

d) retaining as a therapeutic agent, the polypeptide identified in step c), which has the highest or second highest therapeutic index.

16. A therapeutic agent comprising one or more compounds selected from the group consisting of a polypeptide selected according to claim 3, a polynucleotide encoding said polypeptide, a gene expression vector comprising said polynucleotide, and a host cell comprising said gene expression vector.

17. A therapeutic agent selected from the group consisting of a derivative of a polypeptide selected according to claim 3 wherein said derivative has been modified to increase the therapeutic index of said polypeptide, a derivative of a polynucleotide encoding a polypeptide selected according to claim 3, and combinations of the foregoing.

18. A therapeutic agent comprising a recombinant polypeptide whose amino acid sequence comprises more than one natural genetic variation characterizing the polypeptide selected according to claim 3.

19. A method for treating an individual in need thereof comprising administering to said individual a therapeutically effective amount of the therapeutic agent according to claim 16.

20. The method according to claim 3 wherein said therapeutic agent has a new pharmacological profile, a new therapeutic application, or both, with respect to a reference product.

21. The therapeutic agent of claim 17 wherein said modification to said derivative of a polypeptide is selected from the group consisting of PEGylation, glycosylation and succinylation.

22. The therapeutic agent of claim 17 wherein said derivative of a polynucleotide has been modified to increase the therapeutic index of the polypeptide encoded thereby pursuant to a method selected from site directed mutagenesis and directed evolution technologies.